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Abstract 
Chronic demyelination is a pathological hallmark of multiple sclerosis (MS). Only a minority 
of MS lesions remyelinates completely. Enhancing remyelination is, therefore, a major aim of 
future MS therapies. Here we took a novel approach to identify factors that may inhibit or 
support endogenous remyelination in MS. We dissected remyelinated, demyelinated active, 
and demyelinated inactive white matter MS lesions, and compared transcript levels of 
myelination and inflammation-related genes using quantitative PCR on customized TaqMan 
Low Density Arrays. In remyelinated lesions, fibroblast growth factor (FGF) 1 was the most 
abundant of all analyzed myelination-regulating factors, showed a trend towards higher 
expression as compared to demyelinated lesions and was significantly higher than in control 
white matter. Two MS tissue blocks comprised lesions with adjacent de- and remyelinated 
areas and FGF1 expression was higher in the remyelinated rim compared to the demyelinated 
lesion core. In functional experiments, FGF1 accelerated developmental myelination in 
dissociated mixed cultures and promoted remyelination in slice cultures, whereas it 
decelerated differentiation of purified primary oligodendrocytes, suggesting that promotion of 
remyelination by FGF1 is based on an indirect mechanism. The analysis of human astrocyte 
responses to FGF1 by genome wide expression profiling showed that FGF1 induced the 
expression of the chemokine CXCL8 and leukemia inhibitory factor, two factors implicated in 
recruitment of oligodendrocytes and promotion of remyelination. Together, this study 
presents a transcript profiling of remyelinated MS lesions and identified FGF1 as a promoter 
of remyelination. Modulation of FGF family members might improve myelin repair in MS. 
Keywords 
Multiple sclerosis, Remyelination, Demyelination, Fibroblast growth factor 
Introduction 
The adult central nervous system contains a large pool of mitotic oligodendroglial progenitor 
cells (OPCs) which rapidly differentiate and remyelinate lesions in models of toxin or 
immune mediated demyelination [1]. In MS, however, this endogenous repair mechanism 
frequently fails, resulting in the formation of chronic demyelinated plaques with glial scars, 
the pathological hallmark of the disease [2,3]. This has profound functional consequences as 
demyelination not only disrupts saltatory conduction, but also compromises axonal survival 
by enhancing susceptibility to damage by inflammatory mediators [4], and by disrupting 
trophic support provided by myelinating oligodendrocytes [5-7]. The frequently observed 
failure of remyelination in MS does not appear to be due to an intrinsic, absolute defect of 
myelination, because de- and remyelinated MS lesions are frequently found side by side in 
the majority of patients. Furthermore, early MS lesions often show signs of remyelination [8-
12]. 
It is unclear why many MS lesions fail to remyelinate. The presence of OPCs and 
premyelinating oligodendrocytes in many demyelinated lesions [13,14] suggests that this 
could be caused by failure of OPC to differentiate into myelinating oligodendrocytes. 
Overcoming this differentiation block to enhance remyelination by endogenous OPC is 
considered a logical strategy to restore saltatory conduction and reduce accumulation of 
disability due to axonal pathology [15,16]. Achieving this goal, however, is complicated as a 
multitude of cellular and molecular changes within the MS lesions can influence OPC 
migration, survival or differentiation [17-19]. While experimental studies demonstrate that 
many factors can individually influence OPC migration and/or differentiation [20-32], their 
relative expression within MS lesions and their significance in modulating remyelination 
remains unclear. Expression profiling of MS lesions can provide new insight into 
pathomechanisms [33-35], but this approach has not been applied to remyelinated lesions yet. 
To identify endogenous pathways that might be exploited to enhance remyelination we 
analyzed white matter lesions and used qPCR to focus on the expression of genes regulating 
oligodendrocytes. We compared dissected remyelinated lesions, actively demyelinating 
lesions, inactive demyelinated lesions and control white matter. This revealed an important 
role of the FGF family in the regulation of remyelination. The FGF family is known to 
regulate oligodendrocyte biology and myelin thickness [36-40], but its role in MS lesion 
development is unclear. We found that among the analyzed myelination-regulating genes 
FGF1 was the most abundant transcript in remyelinated lesions. In two lesions that contained 
a demyelinated core and a remyelinated rim, the FGF1 transcript levels were higher in the 
remyelinated parts suggesting that the increased availability of FGF1 may support 
remyelination. 
FGF1 has been reported to promote proliferation of glial precursors [41], but had so far not 
been linked to remyelination or its failure in MS. We employed a dissociated myelinating 
culture system [42-44], a remyelinating slice culture model [45,46], a pure oligodendrocyte 
culture, and genome wide expression profiling of astrocytes to deduce the functional 
relevance. This revealed that FGF1 promotes myelination as well as remyelination, 
presumably via an indirect mechanism. In astrocytes, FGF1 induced leukemia inhibitory 
factor (LIF) and the chemokine CXCL8, both implicated in the recruitment of 
oligodendrocytes and the promotion of remyelination. This suggests that also in vivo FGF1 
stimulates astrocytes to release factors promoting remyelination and that selective modulation 
of FGF signaling pathways could provide a novel strategy to enhance remyelination in MS 
and other demyelinating diseases. 
Materials and methods 
Tissue samples 
For mRNA expression analysis we used frozen autoptic tissue samples from the Netherlands 
Brain Bank, the UK MS Brain Bank, the NeuroResource tissue bank, UCL London, and the 
Department of Forensic Medicine, LMU Munich. Twelve tissue blocks from 9 MS patients 
contained 12 white matter lesions, two of them with a demyelinated core and a remyelinated 
rim. As control, we used 6 control tissue blocks from 4 healthy subjects without clinical or 
histological evidence of CNS disease (details in Additional file 1: Table S1). 
For immunostaining of FGF1 we used 10 formalin fixed paraffin embedded (FFPE) tissue 
blocks from 7 MS patients containing remyelinated, demyelinated inactive and demyelinated 
active areas as well as and 3 control tissue blocks form 3 healthy subjects. Most of the 
patients had secondary progressive MS. The mean disease duration was 24 years, the sex 
(f/m) ratio was 2:1 (details in Additional file 1: Table S1). 
MS lesions were classified according to defined criteria: Active lesions contained abundant 
macrophages with degraded myelin products visualized by luxol fast blue (LFB) or oil red O 
staining. Inactive demyelinated lesions were sharply demarcated from the normal appearing 
white matter and largely devoid of macrophages. Remyelinated lesions were sharply 
demarcated from the normal appearing white matter and identified by a fainter LFB staining. 
Tissue has been collected from donors from whom a written informed consent for brain 
autopsy and the use of the material and clinical information for research purposes. 
  
Dissection of brain specimens, RNA extraction, cDNA synthesis, and 
quantitative PCR of brain tissue 
Selected areas from tissue blocks were obtained as follows: Cryosections (20 µm) were 
mounted on PEN slides (P.A.L.M. Microlaser, Bernried, Germany). To identify 
demyelinated, remyelinated, control white matter, and grey matter areas every 6th section (30 
µm) was stained with LFB. The unstained sections were superimposed on LFB stained 
sections and the lesion areas were marked and macrodissected manually. In total 200–300 µm 
of each block was used for transcript analysis. To check the precision of dissection, the 
macrodissected sections were stained with LFB. The control tissue samples used for qPCR 
exclusively contained white matter. Two MS tissue blocks with adjacent de-and remyelinated 
lesions were analyzed individually. 
RNA was obtained from the dissected tissue specimens by guanidinium thiocyanate-phenol-
chloroform extraction (TRI® Reagent, SIGMA, Munich, Germany), and cDNA was 
synthesized using random hexamers (High Capacity cDNA Reverse Transcription kit, 
Applied Biosystems (ABI, Darmstadt, Germany). Subsequently, qPCR was performed using 
custom made TaqMan Low Density Arrays (TLDAs) on the TaqMan 7900 thermocycler 
(both ABI). These TLDAs are based on qPCR reactions performed in 384 well plates with 
prespotted primers for the selected genes. We used the qPCR method for our study, because 
short amplicons (typically < 100 bp) give highly reliable expression data of autoptic tissue, 
both from frozen and in some cases even from FFPE material [47]. We included genes coding 
for factors regulating oligodendrocyte development (46), their receptors (20), myelin 
components (7) and genes that reflect immunological features of the lesions (9). The CNTF 
amplicon we quantified would also detect the ZFP91-CNTF read-through transcript which is 
thought to be non-coding (http://www.ncbi.nlm.nih.gov/gene/386607). Data were analyzed 
using RQ Manager 1.2 software (ABI). We applied three housekeeping genes, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), β-actin (ACTB) and peptidylprolyl 
isomerase A (PPIA). Differential gene expression was determined in 6 demyelinated inactive 
lesions from 4 subjects, 4 remyelinated lesions from 3 subjects, 4 demyelinated active lesions 
from 3 subjects, and 6 control white matter specimens from 4 subjects. 
Histological stainings 
To characterize the tissue lesions, conventional histochemical analysis like LFB and H&E, as 
well as immunohistochemistry for CD68 was used. LFB staining was done on 30 µm thick 
sections for frozen samples and on 4 µm for FFPE samples. Immunostaining for CD68 was 
performed with mouse peroxidase anti peroxidase (PAP) (Dako, Eching, Germany) system 
using diaminobenzidine (DAB) (DAKO) as the chromogenic substrate. 
For FGF1 single staining with DAB, as well as the immunofluorescence staining, additional 
signal amplification was required. Tyramide signal amplification Plus Biotin kit 
(PerkinElmer, Waltham, USA) was used according to manufacturer instructions. To perform 
double staining, immunofluorescence was performed on FFPE sections. The sections (4 µm) 
were first deparaffinised and antigen retrieval was performed by boiling the slides for 30 min 
in Tris-EDTA buffer. To detect FGF1 we applied the mAb 2E12 (ab117640, Abcam, 
Cambridge, UK). This mAb recognizes FGF1 by Western blot, immunocytochemistry and 
flow cytometry, but we cannot exclude some crossreactivity to other FGF family members, 
since the epitope of this mAb has not yet been mapped (information from Abcam). Other 
primary antibodies used were specific for GFAP (Dako), Iba-1 (Wako, Neuss, Germany), 
CD20 (Epitomics, Burlingame, USA) and CD3 (AbD Serotec, Kidlington, UK). Sections 
were incubated with the primary antibody either for 2 hours at RT or overnight at 4°C. The 
following secondary antibodies were used: goat anti-mouse IgG3 Alexa 488, goat anti-mouse 
IgG2a Alexa 488, goat anti-rabbit IgG Alexa 488 (Invitrogen, Karlsruhe, Germany), rat anti-
mouse IgG1 biotinylated (BD, Heidelberg, Germany) and streptavidin Alexa 568 (Invitrogen) 
were used. Negative controls included either isotype specific antibody or the purified IgG. 
All images were acquired on either Leica LMD7000 or Leica DMI6000 microscopes (Leica 
Microsystems, Wetzlar, Germany) and processed using ImageJ software (NIH). 
In vitro myelination (dissociated spinal cord cultures) 
In vitro myelinating cultures were prepared as described before [42-44]. Briefly, neurosphere 
derived astrocytes were grown to confluence. Spinal cord cell suspensions from either E15.5 
Wistar or Sprague Dawley outbred rat strains were plated on the neurosphere derived 
astrocytes. The plating media contained 50% DMEM, 25% heat inactivated horse serum, 
25% HBSS with Ca2+ and Mg2+, and 2 mM L-glutamine. Spinal cord cells were plated in a 
density of 150,000 cells on a 13 mm cover slip, coated with poly-L-lysine. Cells were 
allowed to attach for 2 h at 37°C and subsequently, the plating medium was filled up with 
differentiation medium, containing DMEM (4.5 mg/ml glucose), 10 ng/ml biotin (Sigma), 
0.5% N1 hormone mixture, 50 nM hydrocortisone, and 0.5 mg/ml insulin (Sigma). If not 
mentioned specifically, all the reagents used were from Invitrogen. The final ratio of plating- 
and differentiation-medium was 50/50. Three 13 mm coverslips were kept in 3.5 cm petri 
dishes with a total medium volume of 1 ml. Cultures were maintained at 37°C in7% CO2 and 
fed three times a week by replacing half the culture medium with fresh differentiation media. 
After twelve day insulin was omitted from the culture medium. The cultures were maintained 
for 26–28 days (as indicated in the experiment). For stimulation recombinant human FGF1 
was added together with fresh differentiation medium. 
To access myelination immunocytochemistry was used. Briefly, cells were fixed with 4% 
PFA for 20 min at RT, washed in PBS and permeabilized with 0.5% Triton X-100 and 0.5% 
porcine gelatin for 20 min at RT. Primary antibodies used for the staining were specific for –
neurofilament (SMI-31; Abcam), MBP (Millipore) or myelin oligodendrocyte glycoprotein 
(MOG). Secondary antibodies used were: Goat anti-mouse IgG2a Alexa 488 and goat anti-
mouse IgG1 Alexa 568 (Molecular Probes). Primary antibodies were incubated overnight at 
4°C. Secondary, fluorescence labeled antibodies were incubated for 45 min at room 
temperature and cover slips were mounted with Vectashield (Vector laboratories, 
Peterborough, UK). 
For imaging and quantitative analysis 20–30 images per treatment per experiment were 
acquired at random with a 10X objective using ZEISS AxioVert200M or Olympus BX51 
fluorescent microscope. For each condition 3 coverslips were quantified in each experiment. 
MBP and SMI-31 staining was measured as the pixel value related to the total pixel number 
in the image. The pixel values were calculated using either Metamorph software (series 7.7) 
or Image J (NIH systems, version 1.45) combined with Adobe Photoshop (Elements 7.0). To 
determine the percentage of myelination in each coverslip the number of MBP positive pixels 
was divided by the number of SMI-31 positive pixels. Significance of data values was 
analyzed using T-test. 
Organotypic cerebellar slice cultures 
Organotypic cerebellar slice cultures were prepared and cultured as previously described 
[48]. Briefly, cerebellum and attached hindbrain were extracted from newborn (P0) CD1 
mouse pups (Charles River Laboratories) and cut into 300 µm sagittal sections using a 
McIlwain tissue chopper. Slices were separated and transferred on Millicell-CM culture 
inserts (Millipore, Darmstadt, Germany) in 6-well plates. Culture media was composed of 
50% minimal essential media, 25% heat-inactivated horse serum, 25% Earle’s balanced salt 
solution, 6.5 mg/ml glucose, and penicillin-streptomycin and Glutamax. Membranes were 
transferred into fresh media every 2–3 days. Slices were left untreated for 12 days in vitro to 
allow to myelinate [45]. Subsequently, slices were demyelinated with lysolecithin (0.5 
mg/ml, 16 hours), washed in PBS and allowed to recover in culture media for 1 day. 
Afterwards, the slices were treated with FGF1 (100 ng/ml) for 7 days and 14 days, 
respectively. FGF1 was diluted in culture media and replaced every 2–3 days. Control slices 
remained untreated during the remyelination phase. Although these cultures are used to study 
remyelination, we are aware that they may still be equivalent of developmental myelination 
as the cultures were still at an ex vivo stage during which myelination is continuing in the in 
vivo cerebellum. 
Total RNA from cultured cerebella slices were isolated using the RNeasy Micro Kit (Qiagen, 
Hilden, Germany) according to manufacturer’s protocol. cDNA was generated using the High 
Capacity cDNA Transcription Kit (ABI). All qPCR analysis was conducted using the 
StepOne Plus real time cycler (ABI) and the Power SYBR Green Master Mix (ABI). All 
qPCR results were normalized to human acid ribosomal protein (hARP). 
For immunostaining, slices were fixed in 4% PFA for 1 hour, and then washed twice in PBS. 
Subsequently the slices were blocked for 3 hours at room temperature. The primary antibody 
used recognized MBP (DAKO) and neurofilament (NFL) (DAKO). As secondary antibodies 
we used goat anti-rabbit Cy3 and goat anti-mouse Cy2 (Dianova, Germany). Primary 
antibody was incubated for 48 hours at 4°C, and the secondary, fluorescence labeled 
antibodies were incubated overnight at 4°C and the slices were mounted using Fluorescence 
Mounting Medium (DAKO). 
From these, representative maximal-projection images were generated. The area ratio of 
MBP to NFL immunostaining was determined by drawing along only the filamentous 
structures per image and calculated the area using ImageJ. Per condition three animals were 
used for each of the three experiments. 
Preparation of primary oligodendrocyte progenitor cells (OPCs) 
Primary OPCs were isolated using the immunopanning method as described earlier [49]. 
Briefly, the dissected and chopped forebrains from P6 – P9 day old C57Bl/6 mice were 
incubated for 20 min at 37°C and 5 % CO2 in papain buffer, titruated in ovomucoid solution 
(Cell Systems GmbH, Troisdorf, Germany) and centrifuged at 1000 rpm for 10 min. The cell 
pellet was resuspended in panning buffer and transferred to a negative selection plate coated 
with Anti-BSL 1 Griffonia simplificonia lectin (L-1100, Vector Labs/Biozol, Eching, 
Germany). The supernatant was transferred to a positive selection plate coated with rat anti-
mouse CD140a (10R-CD140AMS, Research Diagnostics/Bioleague, Poggensee, Germany) 
as primary antibody and AffiniPure goat anti-rat IgG (H + L) (112-005-003, Dianova) as 
secondary antibody. After incubation the adherent OPCs were detached by using a cell 
scraper, centrifuged for 10 min at 1000 rpm, resuspended in mouse OPC Sato media [49] and 
plated in T75 culture flask coated with poly-L-lysine. The OPCs were cultured at 37°C and 5 
% CO2; PDGF-AA (10 ng/ml, Peprotech) was added every day. Half of the media was 
changed every second or third day. The purity of the OPCs cultures was more than 95 %. 
Assessment of oligodendroglial proliferation and differentiation 
Proliferation of OPCs was determined using BrdU incorporation (Cell Proliferation ELISA, 
BrdU [colorimetric], Roche Diagnostics, Penzberg, Germany). Oligodendroglial 
differentiation was assessed by morphology. To allow differentiation of OPCs into 
oligodendrocytes, PDGF-AA was replaced by 10 ng/ml ciliary neurotrophic factor (CNTF) 
(Peprotech). Brightfield pictures were taken after 48 h. At least 100 cells per time point were 
classified as oligodendroglial progenitor (0–2 processes), immature (3–13 processes) or 
mature (differentiated cells with myelin sheet formation) oligodendrocytes. 
RNA isolation and qRT-PCR from oligodendrocyte and slice cultures 
Total RNA was isolated using peqGOLD Total RNA Kit and mRNA was transcribed into 
cDNA by reverse transcription reaction (High Capacity cDNA Transcription Kit, ABI). qRT-
PCR was performed using Power SYBR® Green PCR Master Mix (ABI) and StepOne Plus 
real time cycler (ABI). The following primers were used: hARP forward 5’ 
CGACCTGGAAGTCCA-ACTAC 3’; hARP reverse 5’ ATCTGCTGCATCTGCTTG 3’; 
MBP for 5’ GTACAAG-GACTCACACACGAGA 3’; MBP rev 5’ GTTCGAGGTGTCACA 
ATGTTCT 3’; MAG for 5’ ACCGCCTTCAACCTGTCTGT 3’; MAG rev 5’ CTCGTT 
CACAGTCACGTTGC 3’; MOG for 5’ CCTGCAGCACAGACTGAGAGGAAAA 3’; MO 
G rev 5’ TGCTGGGC-TCTCCTTCCGCT 3’. 
Primary astrocyte cell culture, genome wide transcriptome analysis and RT-
qPCR analysis 
Human astrocytes of embryonic origin [50] were cultured as described [51]. Medium was 
changed to serum-free Panserin 401 (PAN Biotech, Aidenbach, Germany) supplemented with 
1 % penicillin-streptomycin 24 h prior to stimulation with recombinant human FGF1 (10 
ng/ml; R&D Systems) and 5 U/ml Heparin-Natrium-25000-ratiopharm® (ratiopharm, Ulm, 
Germany). Astrocytes were stimulated for 8 or 24 hours with FGF1 + heparin or heparin 
alone. Triplicates were analysed for each timepoint. Total RNA from was extracted using 
RNeasy Mini Kit (Qiagen). 200 ng of total RNA was spiked with polyadenylated transcripts 
using the Gene Chip® Poly-A Control kit (Affymetrix, Santa Clara, USA). cRNA was 
generated and transcribed into anti-strand and strand cDNA. The strand cDNA was purified 
using the Ambion WT Expression kit (Life Technologies, Carlsbad, USA) and labeled with 
the Affymetrix GeneChip® WT Terminal Labeling and Control kit (Affymetrix, Santa Clara, 
USA). 
Samples were hybridized to Affymetrix GeneChip® Human Gene 1.0 ST Arrays, containing 
about 29000 probesets representing annotated human transcripts present in NCBI-RefSeq 
database. The arrays were scanned using the GeneChip® 3000 scanner and the transcriptome 
data were exported using AGCC Scan Control software v3.2.3.1515. Subsequently data 
processing and analysis were performed in R/Bioconductor platform 
(www.bioconductor.org). The data were subjected to robust multi-array (RMA) 
normalization [52]. Further, 26839 probesets passed detection above background (DABG) p-
value < 0.05 in at least 25 % of the samples and were considered for the subsequent analysis. 
No outlier samples were identified by principal component analysis and unsupervised 
hierarchical clustering based on filtered genes. Differential expression analysis was 
performed using ebayes test followed by Benjamini&Hochberg method for multiple testing 
correction, as implemented in the LIMMA bioconductor package [53]. Differentially 
expressed probes were defined by three criteria: (a) corrected p-value <0.05, (b) fold change 
threshold ± 1.4 (c), normalized mean expression intensity > = 100 in any one of the two 
groups. 
Reverse transcription qPCR was performed using TaqMan® assays (ABI) to quantify the 
expression of HMOX1 (Hs01110250_m1), CXCL8 (Hs00174103_m1), LIF 
(Hs00171455_m1), and PPIA (4326316E). TaqMan® PCR Core Reagent Kit (ABI) was 
applied, PCR was performed on the 7900HT Fast Real-Time PCR System (ABI) and SDS 
software version 2.3 (ABI) was used for data analysis. 
ELISA 
We used ELISA assays to detect human CXCL8 (#DY208) and human LIF (#DY7734-05) 
(R&D Systems). 3.3′,5.5′-Tetramethylbenzidine (TMB) solution (Sigma-Aldrich) was used as 
substrate and color reaction was stopped by adding 1 mol/l H2SO4. Absorption was measured 
at 450 nm and 540 nm. 
Results 
Astrocyte activation and immune cells in remyelinated lesions 
CD68 and HLA-DR expression was highest in the active lesions (Table 1). Transcripts for 
myelin associated genes were greatly reduced in the demyelinated inactive lesions compared 
to remyelinated lesions (Table 1). The myelin associated genes, were however, not 
completely absent in demyelinated lesions (Table 1), an observation which can be explained 
by the presence of premyelinating oligodendrocytes in the demyelinated lesions [13]. A heat 
map of all analyzed de-and remyelinated lesions, which were dissected based on LFB 
staining, shows that our qPCR results reflected the established pathology of MS lesions 
(Additional file 2: Figure S1). 
Table 1 Expression levels of myelin genes, astrocyte and inflammation markers in MS lesions and their fold changes in demyelinated 
inactive versus remyelinated lesions 
Gene name CWM Remyelinated Demyelinated Active Re/CWM  Re/De  
 mean SEM mean SEM mean SEM mean SEM ratio p ratio p 
Myelin proteins             
CNP 333.38 75.99 539.31 253.33 50.77 20.00 228.49 77.20 1.62 0.48 10.62 0.0095 
MAG 57.21 10.00 65.82 11.80 11.57 6.28 43.18 4.67 1.15 0.76 5.69 0.019 
MBP 40.84 7.40 41.85 13.02 6.91 2.49 107.43 83.98 1.02 0.76 6.06 0.0095 
MOBP 350.12 84.65 422.56 164.85 34.10 18.05 316.04 145.56 1.21 0.91 12.39 0.0095 
MOG 61.33 15.60 90.21 13.05 10.87 5.26 50.26 14.17 1.47 0.26 8.30 0.0095 
OMG 48.67 13.67 86.83 32.00 13.87 4.27 20.85 4.88 1.78 0.35 6.26 0.019 
PLP1 2239.24 486.85 3434.69 397.98. 400.80 143.30 1917.75 252.49 1.53 0.11 8.57 0.0095 
Astrocyte and inflammation markers             
GFAP 890.74 123.37 2713.08 451.88 4715.80 1637.94 11466.90 9726.52 3.05 0.010 0.58 0.91 
CD68 5.57 0.68 11.24 1.00 12.07 3.67 62.60 33.16 2.02 0.010 0.93 1 
HLA-DRA 21.83 6.34 29.63 8.83 20.66 4.05 79.79 7.09 1.36 0.48 1.43 0.35 
IL1B 0.17 0.02 0.14 0.06 0.19 0.10 0.33 0.12 0.80 0.76 0.71 1 
IL10 0.13 0.03 0.24 0.06 0.07 0.03 0.71 0.40 1.82 0.26 3.29 0.040 
TNFSF13B (BAFF) 0.71 0.17 2.04 0.64 0.95 0.27 2.88 1.10 2.88 0.067 2.15 0.26 
TGFB1 5.32 0.99 12.68 2.10 15.03 6.22 106.86 97.86 2.38 0.010 0.84 1 
TGFB2 2.02 0.16 5.08 0.86 7.35 2.66 5.36 0.63 2.52 0.010 0.69 0.76 
TGFB3 4.73 0.70 9.75 4.75 3.09 0.77 8.10 5.37 2.06 0.35 3.15 0.067 
CWM: Control white matter, Remyelinated: Remyelinated lesion, Demyelinated: Demyelinated inactive lesion, Active: Demyelinated active lesion, Re/CWM 
and De/Re ratio: Remyelinated vs. control white matter and vs. demyelinated inactive lesions, respectively; p value were calculated by 2-sided U tests, 
unadjusted for multiple testing. p-values < 0.05 are printed in bold. Specimens analyzed: Six normal white matter specimens from 4 subjects, 6 demyelinated 
inactive lesions from 4 subjects, 4 demyelinated active lesions from 3 subjects, and 4 remyelinated lesions from 3 subjects were dissected and used for qPCR 
analysis. The mean expression values are given as % GAPDH; SEM denotes standard error of the mean. 
In remyelinated lesions, glial fibrillary acidic protein (GFAP) was significantly higher 
expressed than in control white matter, indicating a persistent astrocytic activation in the 
presence of repaired myelin (Table 1). CD68, a marker for microglia activation and 
macrophage infiltration was also significantly elevated in remyelinated lesions (Table 1). B 
cell activating factor of the TNF family (BAFF), a B cell survival factor was also high in 
remyelinated lesions (Table 1), which might reflect the persisting astrocytic activation [51]. 
Altered expression of oligodendrocyte regulators in de- and remyelinated MS 
lesions 
We quantified the expression of mediators regulating oligodendrocytes focusing on 
semaphorins, FGFs, PDGFs, chemokines, IL-6 and IGF family members (Table 2) as well as 
their receptors in the three different lesion types and control white matter (Additional file 3: 
Table S2). 
Table 2 Expression levels of genes potentially regulating oligodendrocytes and their fold changes in demyelinated inactive versus 
remyelinated lesions 
Gene name CWM Remyelinated Demyelinated Active Re/CWMl  Re/De  
 mean SEM mean SEM mean SEM mean SEM ratio p ratio p 
PDGFs             
PDGFA 19.38 2.59 31.78 10.91 15.45 4.47 51.82 34.22 1.64 0.61 2.06 0.26 
PDGFB 1.23 0.28 1.71 0.30 6.79 2.91 31.65 29.42 1.39 0.26 0.25 0.48 
PDGFC 0.52 0.09 1.45 0.47 1.19 0.48 2.56 1.69 2.78 0.038 1.22 0.61 
PDGFD 0.14 0.05 0.37 0.22 0.83 0.46 0.08 0.03 2.61 1.00 0.45 0.45 
FGFs             
FGF1 39.42 2.61 85.40 11.54 48.15 19.53 58.18 16.80 2.17 0.010 1.77 0.11 
FGF2 3.82 0.56 9.23 0.88 10.25 2.62 6.08 0.63 2.41 0.010 0.90 0.91 
FGF5 0.01 0.01 0.00 0.00 0.01 0.01 0.00 0.00 0.00* 0.15 0.00* 0.15 
FGF8 0.00 0.00 0.06 0.05 0.02 0.01 0.01 0.00 16.25* 0.74 2.69* 0.72 
FGF9 0.04 0.02 0.02 0.01 0.87 0.53 0.01 0.00 0.44* 0.71 0.02* 0.066 
Semaphorins             
SEMA3A 0.58 0.11 0.77 0.10 1.77 0.75 0.71 0.25 1.32 0.26 0.43 0.35 
SEMA3B 6.33 1.73 10.48 4.21 2.82 1.50 5.37 3.57 1.66 0.61 3.72 0.11 
SEMA3C 4.84 1.06 7.13 0.75 2.10 0.59 6.13 1.73 1.47 0.17 3.40 0.010 
SEMA3D 0.55 0.09 2.18 0.57 1.08 0.37 0.85 0.23 3.94 0.019 2.02 0.11 
SEMA3E 0.41 0.04 0.91 0.29 0.49 0.15 0.69 0.23 2.21 0.26 1.84 0.17 
SEMA3F 0.02 0.01 0.02 0.01 0.20 0.10 1.91 1.89 0.93* 0.91 0.10* 0.44 
SEMA3G 0.23 0.05 0.16 0.06 0.54 0.31 1.18 0.98 0.68 0.48 0.30 0.91 
SEMA4A 0.22 0.06 0.21 0.05 1.00 0.36 0.29 0.04 0.95 0.91 0.21 0.067 
SEMA4B 2.63 0.31 8.90 2.16 8.46 3.46 18.31 14.74 3.39 0.010 1.05 0.48 
SEMA4C 4.49 0.77 8.07 2.81 3.67 0.83 9.90 6.17 1.80 0.26 2.20 0.11 
SEMA4D 16.61 3.51 24.36 7.25 4.72 2.38 23.80 11.36 1.47 0.61 5.16 0.019 
SEMA4F 0.40 0.04 1.27 0.13 3.09 0.67 4.83 4.19 3.18 0.010 0.41 0.11 
SEMA4G 0.35 0.07 0.44 0.13 0.48 0.28 0.89 0.43 1.26 0.61 0.91 0.59 
SEMA5A 2.38 0.56 3.06 0.45 3.08 1.07 8.98 7.60 1.28 0.61 0.99 0.91 
SEMA5B 0.45 0.09 0.78 0.18 2.34 0.52 1.32 0.53 1.72 0.17 0.33 0.11 
SEMA6A 28.24 6.78 45.65 12.14 12.75 3.45 31.24 4.13 1.62 0.26 3.58 0.010 
SEMA6B 0.73 0.18 1.95 0.78 9.90 4.74 31.22 30.80 2.67 0.07 0.20 0.17 
SEMA6C 0.05 0.01 0.07 0.03 0.13 0.06 0.06 0.02 1.53 0.28 0.54 0.83 
SEMA6D 7.30 1.55 13.26 2.93 4.43 0.84 5.70 1.43 1.82 0.11 3.00 0.019 
SEMA7A 2.85 0.75 3.91 0.35 0.93 0.50 2.99 1.56 1.37 0.48 4.22 0.019 
Chemokines             
CXCL1 0.18 0.07 1.18 0.32 4.46 3.25 1.30 1.04 6.51 0.019 0.27 0.76 
CXCL2 0.17 0.08 0.62 0.14 1.10 0.47 3.49 2.96 3.70 0.019 0.56 0.91 
CXCL8 0.23 0.06 0.51 0.19 0.71 0.15 0.52 0.42 2.22 0.26 0.71 0.61 
CXCL10 0.02 0.01 0.05 0.02 0.04 0.03 0.88 0.47 1.94* 0.76 1.09 0.66 
CXCL12 2.51 0.37 3.65 0.70 30.09 23.06 24.58 16.09 1.45 0.35 0.12 0.76 
IL6 family             
CNTF 0.19 0.04 0.52 0.11 0.20 0.11 0.69 0.50 2.66 0.019 2.65* 0.069 
CLCF1 0.02 0.01 0.16 0.13 0.48 0.23 0.55 0.34 6.62* 0.35 0.34 0.83 
CTF1 0.17 0.03 0.44 0.13 0.82 0.29 1.66 1.36 2.59 0.17 0.54 0.61 
IL6 0.06 0.02 0.07 0.03 0.38 0.31 0.06 0.02 1.27 0.76 0.19 0.83 
IL11 0.01 0.00 0.07 0.05 0.04 0.03 0.02 0.01 5.11* 1.00 1.63 0.91 
LIF 0.01 0.00 0.03 0.02 0.76 0.70 0.43 0.37 5.17* 0.40 0.04 1 
IGFs             
IGF1 0.35 0.10 0.32 0.12 0.63 0.23 1.46 0.98 0.94 1.00 0.51 0.61 
IGF2 0.23 0.01 0.33 0.12 6.04 4.62 1.95 1.23 1.42 0.26 0.06 0.39 
Miscellaneous             
CTGF 1.70 0.50 4.53 0.90 13.40 4.85 9.77 7.80 2.67 0.038 0.34 0.26 
FIGF 0.25 0.07 0.28 0.07 0.60 0.51 0.29 0.10 1.09 0.76 0.46 0.34 
HGF 0.12 0.02 0.37 0.12 0.31 0.14 0.99 0.40 3.05 0.26 1.17 0.45 
LINGO1 0.15 0.11 0.77 0.30 1.42 0.50 0.40 0.14 5.18 0.06 0.54 0.61 
CWM: Control white matter, Remyelinated: Remyelinated lesion, Demyelinated: Demyelinated inactive lesion, Active: Demyelinated active lesion, Re/CWM 
and De/Re ratio: remyelinated vs. control white matter and vs. demyelinated inactive lesions, respectively; p value were calculated by 2-sided U tests, 
unadjusted for multiple testing. p-values < 0.05 are printed in bold. 0.00: Values were below our detection limit, which was 0.01% GAPDH. Specimens 
analyzed: 6 normal white matter specimens from 4 subjects, 6 demyelinated inactive lesions from 4 subjects, 4 demyelinated active lesions from 3 subjects, 
and 4 remyelinated lesions from 3 subjects were dissected and used for qPCR analysis. The mean expression values are given as % GAPDH; SEM denotes 
standard error of the mean. * Ratios may be imprecise since at least one value was below or close to the detection limit. 
SEMA3C, SEMA4D, SEMA6A, SEMA6D, and SEMA7A were significantly higher 
expressed in remyelinated lesions as compared to demyelinated lesions. In contrast SEMA4A 
showed a trend towards higher expression in demyelinated lesions (4.7 fold; p = 0.067; Table 
2). 
LINGO-1 (official gene name LRRN6A) is of great current interest, because it is tested as a 
therapeutic target for MS (EUCTR2011-006262-40-CZ) or First Episode of Acute Optic 
Neuritis (EUCTR2011-006291-39-SE) [54]. Therefore we provide detailed expression data 
for this gene in the different types of MS lesions and control tissue although its biology was 
not further studied here (Additional file 4: Figure S2). 
The receptors ERBB3, FGFR2 and MET were significantly higher expressed in re- versus 
demyelinated lesions (Additional file 3: Table S2). FGFR1, FGFR2, PDGFRB, IL6ST, 
PLXNB1 and CXCR7 were significantly higher expressed in remyelinated lesions compared 
to control white matter (Additional file 3: Table S2). 
FGF1 is abundant in white matter and further increased in remyelinated 
lesions 
FGF1 was the most abundant FGF both in the white matter of the control brain and in the 
white matter MS lesions (Figure 1, Table 2). Further, FGF1 had the highest transcript level of 
all the analyzed myelination-related factors (Figure 1, Table 2) and was therefore further 
studied in detail. In remyelinated lesions, FGF1 showed a trend towards higher expression 
compared to demyelinated lesions and was significantly higher expressed than in control 
white matter (Figure 1, Figures 2a,b). We could directly compare FGF1 expression in two 
tissue blocks with de- and remyelinated areas within the same lesion: in both blocks FGF1 
transcript levels were higher in the dissected remyelinated areas compared to the 
demyelinated lesion core (Figures 2 b-e). 
Figure 1 Oligodendrocyte regulators are differentially expressed in various lesion types. 
MS lesions were dissected from frozen tissue and the expression level of the indicated 
mediators regulating oligodendrocytes were determined by qPCR. The absolute expression 
levels are given in terms of % GAPDH. Displayed is the mean of 6 normal white matter 
specimens, 6 demyelinated inactive, 4 demyelinated active, and 4 remyelinated lesion areas. 
Figure 2 FGF1 expression is elevated in remyelinated lesions. a FGF1 gene expression 
was analyzed by quantitative PCR TLDA relative to GAPDH in individual lesion areas (Re: 
remyelinated, De: demyelinated inactive, Active: actively demyelinating areas) and control 
white matter specimens (Ctrl.). Each symbol represents a single dissected area. Medians 
(bars) and 1st/3rd quartiles (boxes) are shown. Whiskers extend to the range up to 1.5 times of 
the interquartile range; values beyond were regarded as outliers. We noted one outlier in the 
six analyzed demyelinated inactive lesions, but we cannot explain why this one lesion had a 
higher FGF1 level than all others. Regarding the primary topic of remyelination in this study, 
we compared the remyelinated lesions with the other groups of tissue specimens; Mann–
Whitney U test showed a significant difference between the remyelinated areas and controls 
(p < 0.01), while the differences between remyelinated vs. demyelinated inactive areas (p = 
0.1) and remyelinated vs. actively demyelinating areas (p = 0.2) did not reach statistical 
significance. b-d In two blocks, adjacent de- and remyelinated areas were present within the 
same lesion and excised for quantitative PCR TLDA analysis (labelled as Block 1 and 2 for 
Figure 2a-e). FGF1 expression normalized to GAPDH is shown. Fold-changes of FGF1 
expression between the re- and demyelinated areas in each block were calculated for the 
different housekeeping genes. The geometric mean of these fold changes obtained by 
normalization to the three housekeeping genes was 2.1× for block 1 and 4.1× for block 2. 
Accordingly, FGF1 staining was more prominent in the re- compared to the demyelinated 
lesion area (Figures 3 a-c). Analyzing control brain for FGF1 expression, we found cortical 
neurons to be FGF1 positive (Figure 3 d). Furthermore, FGF1 staining was detected in cells 
which, according to their morphology, could be oligodendroglia (Figures 3 e-f). These FGF1-
positive oligodendroglia could also be detected in NAWM of MS brain (data not shown). 
Double staining of FGF1 and GFAP revealed astrocytes in remyelinated lesions to be FGF1 
positive (Figure 4a). In contrast, reactive astrocytes detected in NAWM surrounding the 
lesion areas were FGF1 negative (Figure 4b). In active lesions we detected subsets of 
microglia/macrophages to be FGF1 positive (Figure 4c). Furthermore, subsets of B and T 
cells present in perivascular cuffs displayed an FGF1 staining (Figures 4d, e). Together, our 
stainings localized FGF1 to astrocytes, oligodendrocytes, microglia/macrophages and 
infiltrating lymphocytes, but we cannot conclude from our stainings which cells are the major 
sources and why it is produced. 
Figure 3 FGF1 is expressed in re- and demyelinated lesions as well as in neurons and 
oligodendroglia in control brain and NAWM. a LFB staining of an MS tissue specimen 
with demyelinated (De), remyelinated (Re) lesion areas along with normal appearing white 
mater (NAWM) and gray matter (GM). The FGF staining was more prominent in the 
remyelinated area b compared to the chronic inactive demyelinated area c. In control brain, 
FGF1 staining was detected in neurons of gray matter d and cells appearing as 
oligodendrocytes in WM e, f. Scale bars: 20 µm 
Figure 4 FGF1 is displayed by astrocytes, microglia/macrophages and lymphocytes. 
Double immunofluorescence staining of FGF1 with GFAP a, b, Iba-1 c, CD3 d, and CD20 e. 
Pictures were taken from different areas, namely a chronic inactive demyelinated lesion a, 
NAWM b, chronic active lesion c, and perivascular cuffs in an active lesion d, e. Scale bars: 
a and b 12.5 µm; c, d and e 25 µm. 
FGF1 accelerates developmental myelination in dissociated cultures 
FGF1 was the most abundant of all the myelination-related mediators included in this study 
(Table 2) and was further up-regulated in remyelinated lesions. This led us to speculate that 
increased availability of this member of the FGF family supported lesion repair. The validity 
of this concept was first explored in myelinating cultures derived from embryonic rat spinal 
cord in which myelination is initiated after 12 days in vitro and reaches a plateau two weeks 
later [42,44]. 
Three independent conditions were used to assess ability of FGF1 to stimulate myelination in 
these cultures. First, FGF1 was added for four days after the onset of myelination and this 
enhanced myelination up to 1.7 fold (p < 0.0001) (Figures 5a and 5b). Second, FGF1 was 
added before the onset of myelination at day 12 for a total of 16 days. Again, we observed 
FGF1 enhanced myelination, particularly at 18 and 24 days in vitro (DIV) (Figure 5c). Third, 
FGF1 was added before the onset of myelination for 6 days (12–18 DIV) and then withdrawn 
while myelination was still ongoing. Enhanced myelination could already be detected during 
the initial phase of myelination, was still seen six days after FGF1 was withdrawn and then 
disappeared thereafter (Figure 5d). This indicates that FGF1 accelerates myelination in this 
culture system. 
Figure 5 FGF1 promotes myelination in dissociated spinal cord cultures. Myelinating 
cultures were treated with different concentrations of FGF1 from 22 DIV to 26 DIV and then 
stained for myelin (MBP in green) and axons (SMI-31 in red). a FGF1 treated cultures 
showed enhanced levels of MBP+ myelin sheath as compared to the control cultures. 
Magnification: left panel = 10X, right panel = 40X. b Quantitative evaluation:FG1 promotes 
myelination ****P <0.0001. Error bars represent SEM of two experiments. Myelinating 
cultures were treated with 100 ng/ml FGF1 for different time periods. Axonal density 
calculated as pixel for NFL (different FGF1 dosages/control) were 1.17 for 5 ng/ml FGF1, 
1.2 for 50 ng/ml FGF1 and 1.06 for 50 ng/ml FGF1. c 16 days (12 DIV to 28 DIV) and d 6 
days (12 DIV to 18 DIV). The myelination was enhanced at day 18 and 24, but unaltered at 
day 28. ****P <0.0001. Significance of data values was analyzed using T-test. Error bars 
represent SEM from three independent experiments. The axonal densities (FGF1/control) 
ranged between 0.98 and 1.02 in the experiments shown in c and d. 
FGF1 promotes remyelination in cerebellar slice cultures 
To determine whether FGF1 would also promote remyelination, we investigated its effects on 
demyelinated organotypic cerebellar cultures derived from newborn mouse pups. Slice 
cultures myelinated in vitro in 12 days, they were then demyelinated using lysolecithin and 
allowed to recover in the presence or absence of FGF1. Analysis of cultures 14 days later 
revealed FGF1 promoted remyelination as assessed by immunofluorescence microscopy that 
identified approximately 1.5 fold increase in myelin basic protein (MBP) immunoreactivity 
(Figures 6a and 6b). The MBP expression was normalized based on the axonal density as 
measured by NFL staining. This increase in MBP positive immunoreactivity was paralleled 
by an increase of Mbp transcripts (Figure 6c). Further, we observed an increase in transcript 
level of Mag (Figure 6d), but not consistently of Mog (Figure 6e). 
Figure 6 FGF1 enhances remyelination in organotypic cerebellar slice cultures. After 
toxic demyelination, cerebellar slice cultures were allowed to remyelinate for 14 days in the 
absence or presence of 100 ng/ml FGF1. Myelination was assessed by immunostaining (a, b) 
and quantitative PCR (c–e). a MBP (red), NFL (green) scale bar = 50 µm b Quantification of 
MBP+/NFL+ area ratio in FGF1 treated slices compared to untreated controls. MBP+ myelin 
formation is promoted by FGF1. Students t-test *P = 0.0341. c-e After 14 days RNA was 
extracted, cDNA obtained and transcript levels of c MBP, d Mag and e Mog were measured 
by qPCR. One-way ANOVA **P < 0.01; *P < 0.05; All error bars represent SEM from three 
independent experiments. 
FGF1 decelerates differentiation of monocultured OPCs 
To determine the effect of FGF1 on the proliferation of monocultured oligodendroglial cells 
we cultured OPCs in the presence of PDGF-AA, NT3 and different concentrations of FGF1 
for 24 or 48 hours. No significant influence on the proliferation capacity of OPCs after 24 
and 48 hours compared to controls could be shown by BrdU assays (Figure 7a). To analyse 
effects of FGF1 on oligodendroglial differentiation, different concentrations of FGF1 were 
added to differentiating oligodendrocytes for up to 48 hours. The differentiation of 
oligodendrocytes was analyzed using morphological parameters as well as the mRNA 
expression levels of several genes coding for myelin proteins. Addition of FGF1 for 48 h 
decreased significantly the number of mature oligodendrocytes characterized by multiple 
processes and complex branching (Figure 7b). To further examine the effect on 
oligodendroglial differentiation we analyzed the mRNA expression levels of myelin proteins 
(Mbp, Mag, and Mog) at different time points. The expression levels of all genes were 
significantly down regulated after exposure to FGF1 (Figures 7 c-e). 
Figure 7 FGF1 decelerates differentiation of monocultured oligodendrocytes. a FGF1 
does not affect proliferation of primary murine OPCs but b decelerates the differentiation into 
myelinating oligodendrocytes as determined by morphology; Two-way ANOVA with 
Bonferroni post correction **p < 0.01; *p < 0.05. The expression of myelin-associated genes 
was assessed by quantitative RT-PCR on samples from OPCs (6 h), immature (24 h) and 
mature cells (48 h). The expression levels of c Mbp, d Mag and in e Mog are reduced due to 
increasing FGF1 concentrations; one-way ANOVA with Bonferroni post correction *** p < 
0.001 **P < 0.01; *P = <0.05; error bars represent SEM from three independent experiments. 
FGF1 induces transcriptional changes in human astrocytes including 
upregulation of CXCL8 and LIF 
Since FGF1 is highly abundant in MS lesions (Figure 1) and astrocytes are known to express 
FGFRs [55,56], we analyzed transcriptional responses of human astrocytes to FGF1. First, we 
established the response of our cultured human astrocytes to FGF1 by analyzing the induction 
of HMOX1, which has been reported to be induced in rodent astrocytes by FGF1 [56]. The 
interaction of FGF1 with its receptors is stabilized and stimulation efficacy is increased by 
binding to heparan sulfate [57-60]. Experiments to establish appropriate stimulation 
conditions showed that 5 U/ml heparin and 10 ng/ml FGF1 caused a reliable up-regulation of 
HMOX1, while heparin alone had no effect on (Figure 8 and data not shown). 
Figure 8 FGF1-induced gene expression in human primary astrocytes. (a-c) Gene 
expression was analysed after 8 h (a) and 24 h (b) h with and without FGF1 (10 ng/ml). In all 
experiments, FGF1 was applied together with heparin (5 U/ml); control cultures contained 
heparin only. Only differentially expressed probes (corrected p-value <0.05, fold change > 
1.4-fold up or down, and normalized mean expression intensity ≥ 100 in any one of the two 
groups) are shown. The number of differentially expressed probes is shown in a. CXCL8 and 
LIF were among the genes upregulated at both time points (see also Additional file 5: Table 
S3). (d) For validation, CXCL8, LIF, and the positive control HMOX1 gene expression were 
analysed by quantitative PCR after 8 h and 24 h with FGF1 (10 ng/ml). (e) Secreted CXCL-8 
and LIF protein were measured by ELISA in the supernatant after 8 and 24 h with and 
without 10 ng/ml FGF1. In (d,e), the fold-change compared to unstimulated control cultures 
is displayed. Black bars and boxes indicate medians and 1st/3rd quartiles, respectively. 
Whiskers extend to the most extreme samples up to 1.5× of the IQR. Red bars indicate 
means. Fold-changes were analysed by two-sided one-sample tests against the control 
samples (µ = 1; t-test for FGF1 mRNA, U test for FGF1 protein because of non-normal 
distribution). *: p < 0.05, **: p < 0.01. 
Further, the effects of FGF1 stimulation on primary human astrocytes were investigated using 
an Affymetrix GeneChip® Human Gene 1.0 ST Array. Triplicate samples were analyzed at 8 
h and 24 h. Differential expression analysis between FGF-treated astrocytes and control 
cultures identified 292 probe sets (154 upregulated and 138 downregulated) at 8 h and 933 
probe sets (521 upregulated and 412 downregulated) at 24 h (Figures 8a-c). Accordingly, 
unsupervised hierarchical clustering based on the transcriptional signatures at 8 and 24 h 
clustered together the FGF1 replicates and classified them apart from the control replicates 
(heatmaps in Figures 8b,c). Interestingly, 245 out of 292 (about 85%) of differentially 
expressed probe sets at 8 h maintained differential expression at 24 h. All probe sets regulated 
by FGF1 at 8 and 24 h and the genes they represent are shown in Additional file 5: Table S3. 
Among these genes regulated by FGF1 were two released factors that had been linked 
previously to remyelination, namely LIF and CXCL8. We then validated the induction of 
CXCL8 and LIF in human astrocytes by FGF1 further by both qPCR and ELISA (Figures 
8d,e). 
Discussion 
This study presents a quantitative expression analysis of remyelinated MS lesions. We 
describe a complex change of multiple factors known to affect oligodendrocyte proliferation 
and maturation. Among all 46 analyzed factors, FGF1 was the most abundant one in shadow 
plaques and was further induced in these lesions. In functional experiments with dissociated 
myelinating cultures and remyelinating slice cultures, we found that FGF1 promotes both 
developmental myelination and remyelination. 
FGF family members are widely expressed in the brain, and are recognized as determinants 
of neuronal survival during development and adulthood [61]. Here we identified a role for 
FGF1 in promoting remyelination with potential relevance for repair in human MS. This is 
consistent with previous findings showing a role of the FGF family in myelination [39,62,63]. 
In MS lesions, FGF1 was localized on astrocytes, neurons, oligodendrocytes, microglia and 
infiltrating T cells and B cells. Previously FGF1 was reported in neurons [64] and reactive 
astrocytes in Alzheimer’s disease [65]. In an animal model of chemically induced 
demyelination, enhanced expression of FGF1 was described during remyelination [66]. Our 
qPCR analysis indicated a higher level of FGF1 also in active lesions. In addition, our 
immunostaining localized FGF1 on T cells and microglia in active MS lesions. FGF1 could 
be produced by these cells themselves or alternatively been picked up after release from 
surrounding cells. Our qPCR shows that in normal brain and in the different MS lesions, 
FGF1 is abundantly transcribed, but the precise stimuli triggering FGF1 expression during 
experimental de- and remyelination and in remyelinated MS lesions remain to be identified. 
MS lesions frequently show a demyelinated core and a remyelinating ring [11]. Examining 
two such tissue blocks we found FGF1 to be higher in the remyelinated rim compared to the 
demyelinated core. This further indicates that success of remyelination is associated with 
increased levels of FGF1. The up-regulation of FGF1 was found in remyelinated areas, in 
which the repair had already been carried out before. Therefore our tissue analysis would not 
allow concluding whether FGF1 is involved in active remyelination and/or maintenance of 
remyelinated myelin sheaths. Our functional experiments, however, indicate that FGF1 has a 
role in the active myelination and remyelination process. In an in vitro culture system 
recapitulating essential features of myelination [42-44] we found FGF1 to promote 
developmental myelination. The significance of the FGF family in developmental 
myelination has been established in vivo: Fibroblast growth factor receptor (FGFR) signaling 
is required for the generation of OPCs from the embryonic forebrain [63]. Remyelination and 
developmental myelination share essential features, but possible differences between 
development and repair have to be considered [67]. Therefore, we employed a slice culture 
model [45,48] and found that FGF1 promoted also remyelination. 
Our further experiments with pure cultures of oligodendrocytes and astrocytes suggest that 
the (re)myelination promoting effect of FGF1 is mediated by an indirect mechanism: FGF1 
promoted (re)myelination in mixed cultures and slice cultures that contained 
oligodendrocytes, microglia, and astrocytes. In pure oligodendrocyte cultures, however, 
FGF1 did not induce proliferation and inhibited the differentiation. Therefore we analyzed if 
FGF1 might induce myelination-promoting factors in astrocytes. We switched for these 
experiments to human astrocytes, since understanding of regulation of remyelination in MS is 
our purpose. We found that FGF1 induced LIF and CXCL8 in primary human astrocytes. 
CXCL8, which does not have a homologue in rats and mice, is not only a chemoattractant for 
monocytes and neutrophils, but also recruits oligodendrocyte progenitor cells [68]. CXCL8 
was detected in astrocytes around active MS lesions [69]; its receptors CXCR2 and CXCR1 
[70] were found on oligodendrocyte precursor cells [71] and, importantly, upregulated on 
oligodendrocytes around MS lesions [68]. CXCL8 was therefore suggested to be involved in 
regeneration of MS lesions [69]. LIF has been established to support oligodendrocyte 
survival in vitro [72,73] and in vivo [74,75] as well as to promote myelination [76]. In EAE 
models, LIF directly prevented oligodendrocyte cell death [74] and promoted remyelination 
[77]. Together, we found that human astrocytes produce CXCL8 and LIF in response to 
FGF1, and these findings together with our results obtained with rodent culture systems 
(myelinating dissociated cultures, remyelinating slice cultures, and pure oligodendrocytes) 
indicate that FGF1 promotes the induction of (re)myelination indirectly via an effect 
mediated by astrocytes, although the relative importance of different FGF1-induced factors in 
the rodent models of remyelination remains to be specified. One constant feature of 
remyelination is that the repaired myelin is thinner than the original myelin [78], but it is 
unclear why this is the case. Previous findings that FGFR signaling regulates myelin 
thickness in development [39] raise the possibility that FGFs may participate in the regulation 
of this aspect of remyelination. 
Beyond the FGF-family, our study provides quantitative information on additional regulators 
of oligodendrocytes biology in de- and remyelinated human MS lesions such as Lingo-1, 
which is a target in current clinical trials [27,54]. Semaphorins were originally identified as 
axonal guidance cues, but they also regulate migration and oligodendrocyte biology 
[29,31,79]. We noted that 5 semaphorins (3C, 4D, 6A, 6D, and 7A) were significantly higher 
expressed in re- versus demyelinated lesions. Sema6A and Sema6D had not been linked 
before to remyelination in MS. All this inspires further studies on the role of semaphorins in 
the regulation of remyelination in MS. 
Mediators commonly used to promote oligodendrocyte cultures such as FGF2, PDGF, ciliary 
neurotrophic factor (CNTF), IGFs, and IL-11 were present or even enhanced in inactive 
demyelinated MS lesions. This adds to the view that it is not the scarcity or even lack of one 
specific factor in the inactive demyelinated lesions that can explain the failure of 
remyelination. Since myelination depends on a delicate and fine-tuned balance of many 
factors [78], the multiple alterations observed here (Table 1) may well contribute to the 
failure of remyelination together with the induction of inhibitory mechanisms. 
In summary, we present a quantitative analysis of oligodendrocyte regulators in remyelinated 
MS lesions. We report that success of remyelination in MS is accompanied by high levels of 
FGF1 and that FGF1 enhances myelination and remyelination in vitro presumably via an 
indirect mechanism mediated by astrocytes. Targeting FGF family members may have 
therapeutic potential [80], and should be tested to enhance repair in MS. 
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Additional file 2: Figure S1. Unsupervised clustering reflects histological discrimination between remyelinated (blue) and
demyelinated inactive (pink) lesion areas (125k)
http://www.actaneurocomms.org/content/supplementary/s40478-014-0168-9-s2.pdf
Additional file 3: Table S2. Expression levels of receptors and their fold changes in demyelinated inactive versus
remyelinated lesions (29k)
http://www.actaneurocomms.org/content/supplementary/s40478-014-0168-9-s3.docx
Additional file 4: Figure S2. LRRN6A (LINGO-1) gene expression in different MS lesion types and control white matter
(91k)
http://www.actaneurocomms.org/content/supplementary/s40478-014-0168-9-s4.pdf
Additional file 5: Table S3. Transcriptional changes induced by FGF1 in human primary astrocytes, after 8 and 24 h (34k)
http://www.actaneurocomms.org/content/supplementary/s40478-014-0168-9-s5.xlsx
